Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Neuronetics, Inc. commercial stage medical technology company. The company is headquartered in Malvern, Pennsylvania and currently employs 191 full-time employees. The firm is focused on the design and development of medical devices to treat psychiatric disorders. The Company’s principal product is NeuroStar Advanced Therapy System. The company is a non-invasive treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed magnetic field to induce electrical pulses for stimulating certain areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorders. The firm offers its therapy systems to psychiatrist offices in the United States.
Website: neurostar.com



Growth: Good revenue growth rate 11.1%, there is slowdown compared to average historical growth rates 14.6%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -38.9%. On average the margin is improving steadily. Gross margin is high, +75.2%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -31.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 232.4% higher than minimum and 79.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 0.3x by EV / Sales multiple , the company can be 79.3% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.6 mln (-0.623% of cap.)

Key Financials (Download financials)

Ticker: STIM
Share price, USD:  (-0.9%)3.49
year average price 2.45  


year start price 2.29 2023-04-29

min close price 1.05 2023-10-26

max close price 4.81 2024-04-01

current price 3.49 2024-04-27
Common stocks: 29 048 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  11.1%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  14.6%
Historical growth of EBITDA:  0.0%
EV / Sales: 1.4x
Margin (EBITDA LTM / Revenue): -38.9%
Fundamental value created in LTM:
Market Cap ($m): 101
Net Debt ($m): 1
EV (Enterprise Value): 102
Price to Book: 3.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-01Zacks Investment Research

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

2024-03-05Zacks Investment Research

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

2023-09-06Seeking Alpha

Neuronetics: Large Losses May Be Repelling Investors

2023-08-08Seeking Alpha

Neuronetics, Inc. (STIM) Q2 2023 Earnings Call Transcript

2023-05-24GlobeNewsWire

Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference

2023-05-13Seeking Alpha

Neuronetics, Inc. (STIM) Q1 2023 Earnings Call Transcript

2023-05-09GlobeNewsWire

Neuronetics to Present at the JMP Securities Life Sciences Conference

2023-04-25GlobeNewsWire

Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol STIM STIM STIM STIM STIM STIM
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-08 2023-11-07 2023-08-08 2023-05-15 2023-03-07 2022-11-08
acceptedDate 2024-03-07 21:44:57 2023-11-07 16:30:33 2023-08-08 16:31:51 2023-05-15 16:31:15 2023-03-07 16:39:58 2022-11-08 16:31:02
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 20M 18M 18M 16M 18M 16M
costOfRevenue 5M 6M 5M 4M 4M 4M
grossProfit 15M 12M 13M 11M 14M 13M
grossProfitRatio 0.752 0.658 0.725 0.733 0.759 0.784
researchAndDevelopmentExpenses 2M 2M 2M 3M 3M 2M
generalAndAdministrativeExpenses 6M 6M 6M 7M 6M 6M
sellingAndMarketingExpenses 12M 12M 12M 12M 12M 12M
sellingGeneralAndAdministrativeExpenses 17M 18M 18M 19M 18M 18M
otherExpenses 894 000 664 000 4M 640 000 649 000 0
operatingExpenses 20M 21M 20M 21M 22M 20M
costAndExpenses 25M 27M 25M 25M 26M 24M
interestIncome 0 520 000 452 000 0 0 0
interestExpense 2M 1M 1M 1M 1M 1M
depreciationAndAmortization 503 000 499 000 488 000 1M 649 000 1M
ebitda -4M -8M -3M -9M -7M -6M
ebitdaratio -0.193 -0.431 -0.186 -0.563 -0.389 -0.373
operatingIncome -4M -9M -7M -10M -8M -7M
operatingIncomeRatio -0.218 -0.496 -0.417 -0.638 -0.425 -0.452
totalOtherIncomeExpensesNet -950 000 664 000 4M -613 000 -563 000 -155 000
incomeBeforeTax -5M -9M -5M -11M -8M -8M
incomeBeforeTaxRatio -0.265 -0.525 -0.278 -0.677 -0.455 -0.461
incomeTaxExpense 0 2M 5M 613 000 562 000 155 000
netIncome -5M -9M -5M -11M -9M -8M
netIncomeRatio -0.265 -0.525 -0.278 -0.716 -0.486 -0.471
eps -0.190 -0.330 -0.170 -0.400 -0.330 -0.290
epsdiluted -0.190 -0.330 -0.170 -0.400 -0.330 -0.290
weightedAverageShsOut 29M 29M 29M 28M 27M 27M
weightedAverageShsOutDil 29M 29M 29M 28M 27M 27M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol STIM STIM STIM STIM STIM STIM
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-08 2023-11-07 2023-08-08 2023-05-15 2023-03-07 2022-11-08
acceptedDate 2024-03-07 21:44:57 2023-11-07 16:30:33 2023-08-08 16:31:51 2023-05-15 16:31:15 2023-03-07 16:39:58 2022-11-08 16:31:02
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 60M 36M 46M 55M 70M 74M
shortTermInvestments 905 000 968 000 1M 1M 2M 2M
cashAndShortTermInvestments 61M 37M 47M 57M 72M 76M
netReceivables 18M 17M 15M 11M 14M 12M
inventory 8M 10M 9M 9M 9M 9M
otherCurrentAssets 7M 5M 5M 2M 2M 5M
totalCurrentAssets 94M 71M 78M 81M 99M 101M
propertyPlantEquipmentNet 5M 5M 5M 5M 5M 6M
goodwill 0 0 0 0 0 0
intangibleAssets 4M 0 0 0 0 0
goodwillAndIntangibleAssets 4M 0 0 0 0 0
longTermInvestments 4M 700 000 859 000 989 000 1M 2M
taxAssets -4M 0 0 0 0 0
otherNonCurrentAssets 13M 16M 17M 16M 12M 11M
totalNonCurrentAssets 22M 22M 23M 22M 18M 18M
otherAssets 1.000 0 0 0 0 0
totalAssets 116M 93M 100M 104M 117M 119M
accountPayables 5M 3M 4M 5M 2M 2M
shortTermDebt 845 000 840 000 834 000 829 000 14M 10M
taxPayables 818 000 641 000 701 000 674 000 659 000 558 000
deferredRevenue 2M 2M 2M 2M 2M 2M
otherCurrentLiabilities 13M 10M 8M 7M 15M 11M
totalCurrentLiabilities 20M 15M 15M 15M 33M 25M
longTermDebt 59M 39M 39M 39M 26M 30M
deferredRevenueNonCurrent 200 000 354 000 513 000 671 000 829 000 981 000
deferredTaxLiabilitiesNonCurrent 0 37M 37M 0 0 0
otherNonCurrentLiabilities 2M -37M -37M 0 0 17M
totalNonCurrentLiabilities 62M 40M 40M 40M 27M 31M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 2M 3M 3M 4M 4M 4M
totalLiabilities 82M 55M 55M 55M 60M 56M
preferredStock 0 0 0 0 0 0
commonStock 291 000 289 000 288 000 285 000 273 000 270 000
retainedEarnings -376M -371M -361M -356M -346M -338M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0
othertotalStockholdersEquity 410M 408M 407M 404M 403M 400M
totalStockholdersEquity 34M 38M 45M 48M 57M 63M
totalEquity 34M 38M 45M 48M 57M 63M
totalLiabilitiesAndStockholdersEquity 116M 93M 100M 104M 117M 119M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 116M 93M 100M 104M 117M 119M
totalInvestments 5M 700 000 859 000 2M 3M 3M
totalDebt 62M 40M 40M 40M 40M 40M
netDebt 3M 4M -6M -15M -31M -34M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol STIM STIM STIM STIM STIM STIM
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-08 2023-11-07 2023-08-08 2023-05-15 2023-03-07 2022-11-08
acceptedDate 2024-03-07 21:44:57 2023-11-07 16:30:33 2023-08-08 16:31:51 2023-05-15 16:31:15 2023-03-07 16:39:58 2022-11-08 16:31:02
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -5M -9M -5M -11M -8M -8M
depreciationAndAmortization 503 000 499 000 488 000 516 000 604 000 387 000
deferredIncomeTax 89 000 3M -266 000 0 0 0
stockBasedCompensation 2M 2M 2M 2M 2M 2M
changeInWorkingCapital 5M -6M -13M -1M 2M -2M
accountsReceivables -898 000 -2M -10M 4M -2M -572 000
inventory 2M -3M 236 000 -243 000 -288 000 -1M
accountsPayables 2M -2M -907 000 2M 231 000 57 000
otherWorkingCapital 2M 970 000 -2M -7M 4M 338 000
otherNonCashItems 106 000 138 000 134 000 188 000 196 000 173 000
netCashProvidedByOperatingActivities 2M -10M -15M -9M -3M -7M
investmentsInPropertyPlantAndEquipment -879 000 -552 000 -704 000 -234 000 -503 000 -726 000
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 535 000 725 000 0
otherInvestingActivites 316 000 618 000 6M -7M -725 000 10M
netCashUsedForInvestingActivites -563 000 66 000 6M -6M -503 000 9M
debtRepayment -22M 0 -62 000 -1M -34 000 0
commonStockIssued 1000.000 0 0 0 298 000 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 45M 0 0 2M -19 000 0
netCashUsedProvidedByFinancingActivities 22M 0 -62 000 499 000 245 000 0
effectOfForexChangesOnCash -29M 0 -546 000 0 0 0
netChangeInCash 24M -10M -10M -15M -3M 3M
cashAtEndOfPeriod 60M 36M 46M 55M 70M 74M
cashAtBeginningOfPeriod 36M 46M 55M 70M 74M 71M
operatingCashFlow 2M -10M -15M -9M -3M -7M
capitalExpenditure -879 000 -552 000 -704 000 -234 000 -503 000 -726 000
freeCashFlow 1M -11M -16M -9M -4M -7M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-03-05 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-13 ET (fiscal 2023 q1)
2022 q4
2023-03-07 ET (fiscal 2022 q4)
2022 q3
2022-11-11 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-12 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-03-05 12:30 ET
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
2024-02-20 13:30 ET
Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
2024-02-12 13:32 ET
Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
2024-02-06 13:28 ET
NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
2024-01-08 13:30 ET
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
2023-12-18 13:49 ET
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
2023-12-04 13:56 ET
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
2023-11-15 21:15 ET
Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference
2023-11-13 13:57 ET
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
2023-11-09 13:32 ET
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
2023-11-07 12:30 ET
Neuronetics Reports Third Quarter 2023 Financial and Operating Results
2023-11-06 21:30 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-10-24 12:30 ET
Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call
2023-10-16 12:56 ET
Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes
2023-10-03 13:21 ET
Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility
2023-09-12 12:56 ET
In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression
2023-08-21 12:56 ET
NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards
2023-08-14 13:02 ET
Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform
2023-08-08 11:30 ET
Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results
2023-08-04 20:30 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-07-25 12:30 ET
Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call
2023-07-19 12:56 ET
Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans
2023-07-17 12:46 ET
NeuroStar Achieves Milestone Regulatory Clearance in South Korea
2023-07-11 12:56 ET
NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player
2023-06-12 12:59 ET
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
2023-05-30 17:50 ET
Neuronetics investing in NeuroStar awareness as drug-free treatment alternative for depression
2023-05-26 12:59 ET
Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan
2023-05-24 20:30 ET
Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference
2023-05-23 12:46 ET
New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
2023-05-15 12:56 ET
Neuronetics Wins 2023 Bell Seal for Workplace Mental Health
2023-05-09 21:00 ET
Neuronetics to Present at the JMP Securities Life Sciences Conference
2023-05-09 11:30 ET
Neuronetics Reports Record First Quarter 2023 Financial and Operating Results
2023-05-08 12:47 ET
Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR
2023-05-05 12:30 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-05-03 12:58 ET
Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
2023-05-02 13:01 ET
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
2023-05-01 12:46 ET
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
2023-04-28 20:11 ET
Neuronetics Announces Expanded TMS Access through United HealthCare
2023-04-25 12:30 ET
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
2023-04-13 12:58 ET
Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
2023-04-06 20:16 ET
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities
2023-04-04 12:30 ET
Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note
2023-03-16 12:56 ET
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
2023-03-07 12:30 ET
Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results
2023-03-02 21:02 ET
Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives
2023-02-27 21:30 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-02-23 13:56 ET
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
2023-02-22 21:35 ET
Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call
2023-02-21 13:53 ET
Neuronetics Sponsors the 5th International Brain Stimulation Conference
2023-02-16 21:12 ET
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
2023-02-10 21:15 ET
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
2023-01-19 13:30 ET
Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership
2023-01-18 21:29 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-01-17 13:32 ET
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
2023-01-10 13:00 ET
Neuronetics Settles Litigation Against BrainsWay
2023-01-09 13:30 ET
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
2022-12-29 21:29 ET
Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors
2022-12-07 21:30 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-12-05 13:32 ET
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
2022-11-21 21:30 ET
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
2022-11-14 13:33 ET
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
2022-11-10 01:04 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-11-08 12:30 ET
Neuronetics Reports Third Quarter 2022 Financial and Operating Results
2022-10-31 12:31 ET
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
2022-10-25 14:31 ET
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
2022-10-25 12:30 ET
Neuronetics to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call
2022-09-26 12:31 ET
Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
2022-09-13 12:33 ET
Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony
2022-08-29 12:30 ET
Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health
2022-08-05 20:30 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-08-02 12:00 ET
Neuronetics Reports Second Quarter 2022 Financial and Operating Results
2022-07-28 20:30 ET
Neuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference
2022-07-25 12:31 ET
Neuronetics and Alleviant Health Centers Announce Exclusive Partnership
2022-07-19 12:30 ET
Neuronetics to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call
2022-07-19 11:00 ET
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression
2022-07-13 12:31 ET
Neuronetics Recognized as Top Non-Invasive Devices Provider in 2022
2022-07-11 20:46 ET
Neuronetics Announces Positive TMS Coverage Policies to Expand Patient Access to NeuroStar TMS Therapy for Mental Health
2022-05-25 20:30 ET
Neuronetics to Present at the William Blair 42nd Annual Growth Stock Conference
2022-05-17 12:31 ET
New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy
2022-05-12 11:30 ET
Neuronetics Reports First Quarter 2022 Financial and Operating Results
2022-05-11 20:30 ET
Neuronetics and Transformations Care Network Announce Extended Commercial Partnership
2022-05-11 12:31 ET
Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting
2022-05-11 12:00 ET
Neuronetics Files Federal Lawsuit Against Brainsway for Misleading Psychiatrists and Patients
2022-05-10 12:31 ET
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder
2022-05-06 20:30 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-05-03 16:59 ET
NeuroStar Advanced Therapy for Mental Health Announces Partnership with Mental Health Advocate and Former Major League Baseball Player Drew Robinson
2022-04-28 12:30 ET
Neuronetics to Report First Quarter 2022 Financial and Operating Results and Host Conference Call
2022-04-11 12:00 ET
Greenbrook and Neuronetics Announce Strengthened Commercial Partnership to Build Awareness
2022-03-08 21:35 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-03-08 12:30 ET
Neuronetics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
2022-03-03 15:00 ET
NeuroStar® Advanced Therapy Launches New “Tap Into a New Possibility” Campaign for Depression Awareness
2022-03-01 13:31 ET
MT Cap for NeuroStar Advanced Therapy for Mental Health Now Available Nationwide
2022-02-22 21:30 ET
Neuronetics to Report Fourth Quarter and Fiscal Year 2021 Financial and Operating Results and Host Conference Call
2022-02-22 12:30 ET
Neuronetics Announces Amendment of Credit Facility with SLR Investment Corp.
2022-01-10 13:31 ET
NeuroStar Advanced Therapy for Mental Health Recognized as Top Neuromodulation Solution Provider in 2021
2022-01-10 13:30 ET
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results
2021-12-20 13:31 ET
Neuronetics Announces 510(k) Clearance of MT Cap Technology for NeuroStar® Advanced Therapy for Mental Health
2021-12-06 13:31 ET
Neuronetics Announces Key Role for NeuroStar Advanced Therapy at 4th International Brain Stimulation Conference
2021-11-22 21:30 ET
Neuronetics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
2021-11-09 12:30 ET
Neuronetics Reports Third Quarter 2021 Financial and Operating Results
2021-11-08 15:00 ET
Neuronetics and River Region Psychiatry Announce Exclusive Partnership
2021-10-26 12:30 ET
Neuronetics to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call
2021-10-26 12:30 ET
Neuronetics Celebrates 235,000 Treatment Milestone for Success TMS
2021-10-20 00:15 ET
CORRECTION - Neuronetics Announces Preliminary Revenue for Third Quarter 2021
2021-10-19 12:31 ET
Neuronetics Launches Upgrades of NeuroStar® Advanced Therapy for Mental Health
2021-10-12 20:15 ET
Neuronetics Announces Preliminary Revenue for Third Quarter 2021
2021-10-05 20:15 ET
Neuronetics Announces Commercial Agreement with Success TMS
2021-10-04 12:40 ET
NeuroStar® Advanced Therapy Recognizes National Depression Education and Awareness Month With New Campaign Launch
2021-09-22 22:33 ET
UPDATE - New Data Highlights NeuroStar® Advanced Therapy for Mental Health Safety Over H-Coil TMS
2021-09-21 12:30 ET
New Data Highlights NeuroStar® Advanced Therapy for Mental Health Safety Over H-Coil TMS
2021-09-07 12:30 ET
Neuronetics and Zion Healing Announce First Franchise Model for TMS Clinics
2021-08-17 12:31 ET
Neuronetics Launches New Website to Meet Patient Demand for Depression Resources
2021-08-05 20:30 ET
Neuronetics Announces Appointment of Megan Rosengarten to its Board of Directors
2021-08-03 11:30 ET
Neuronetics Reports Second Quarter 2021 Financial and Operating Results
2021-07-29 12:30 ET
Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference
2021-07-20 12:30 ET
Neuronetics to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call
2021-07-14 12:15 ET
Neuronetics Launches Enhanced Digital Resource Center for NeuroStar Providers
2021-06-23 21:29 ET
Neuronetics Set to Join Russell 2000® Index
2021-06-09 12:00 ET
Neuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting
2021-06-03 12:00 ET
Neuronetics to Present at The JMP Securities Life Sciences Conference
2021-06-01 12:00 ET
Neuronetics Names Todd Cushman as Vice President, Business Development
2021-05-20 12:00 ET
Neuronetics to Present at the William Blair 41st Annual Growth Stock Conference
2021-05-17 12:00 ET
Neuronetics® Celebrates 100,000 Treatment Milestone for Southern California TMS Center
2021-05-04 11:00 ET
Neuronetics Reports First Quarter 2021 Financial and Operating Results
2021-05-03 12:00 ET
Neuronetics Employee Patient Advocates Honor Mental Health Awareness Month by Sharing Personal Depression Experiences
2021-04-29 12:00 ET
Neuronetics To Present Clinical Data at The American Psychiatric Association 2021 Annual Meeting
2021-04-20 12:00 ET
Neuronetics to Report First Quarter 2021 Financial and Operating Results and Host Conference Call
2021-04-14 21:15 ET
Neuronetics Announces Retirement of Brian Farley and Appointment of Robert Cascella as Chairman of its Board of Directors
2021-04-01 20:05 ET
Neuronetics Announces Appointment of Robert Cascella to its Board of Directors
2021-03-11 21:25 ET
Neuronetics Announces Retirement of Gregory Harper, Vice President, R&D and Clinical
2021-03-09 13:00 ET
Neuronetics Enhances TrakStar® Cloud Patient Data Management System to Maximize Physician Efficiencies
2021-03-03 13:00 ET
Neuronetics Names Cory Anderson Vice President, Clinical Affairs and Medical Operations
2021-03-02 12:30 ET
Neuronetics Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
2021-02-23 13:00 ET
NeuroStar® Advanced Therapy Outcomes Registry Clinical Data Published in Brain Stimulation Validates Depression Treatment Protocols
2021-02-16 12:00 ET
Neuronetics to Report Fourth Quarter and Fiscal Year 2020 Financial and Operating Results and Host Conference Call
2021-02-11 13:00 ET
Neuronetics Announces Strategic Leadership Promotions to Support Future Growth
2021-02-10 12:00 ET
Neuronetics to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2021-02-02 21:05 ET
Neuronetics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
2021-01-29 03:29 ET
Neuronetics Announces Pricing of $75 Million Public Offering of Common Stock
2021-01-28 21:01 ET
Neuronetics Announces Proposed Public Offering of Common Stock
2021-01-19 13:00 ET
NeuroStar® Advanced Therapy’s Depression Outcomes Registry Hits 10,000 Patient Milestone
2021-01-12 21:05 ET
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results
2021-01-07 21:30 ET
Neuronetics to Participate at the 23rd Annual ICR Westwicke Conference
2021-01-07 13:00 ET
Neuronetics Announces Expansion of Sales Organization
2020-12-08 21:05 ET
Neuronetics Announces the Amendment of Credit Facility with Solar Capital Partners
2020-11-30 21:05 ET
Neuronetics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-23 21:05 ET
Neuronetics® Receives FDA Clearance for Three-Minute TouchStar™ Treatment Protocol
2020-11-12 21:05 ET
Neuronetics to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
2020-11-02 21:05 ET
Neuronetics Reports Third Quarter 2020 Financial and Operating Results
2020-10-19 20:05 ET
Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call
2020-10-13 12:00 ET
Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar® Advanced Therapy as a First-line Treatment for Major Depressive Disorder
2020-10-05 12:00 ET
Neuronetics Appoints Sara Grubbs as Vice President, Sales
2020-10-01 12:00 ET
NeuroStar® Advanced Therapy Providers Offer Free TMS Consultations During National Depression Awareness Month
2020-09-29 12:00 ET
Neuronetics® Celebrates 500,000 Treatment Milestone for Greenbrook® TMS
2020-09-22 12:00 ET
Neuronetics Unveils New Depression Data at Clinical TMS Society’s Virtual Events
2020-08-04 11:30 ET
Neuronetics Reports Second Quarter 2020 Financial and Operating Results
2020-07-21 12:00 ET
Neuronetics to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call
2020-07-17 20:05 ET
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2020-07-14 20:15 ET
Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer
2020-07-14 20:05 ET
Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer
2020-06-26 11:00 ET
Neuronetics Announces Appointment of Bruce J. Shook to its Board of Directors
2020-06-04 20:30 ET
Neuronetics to Present at the William Blair 40th Annual Growth Stock Conference
2020-05-12 21:20 ET
Neuronetics, Inc. Announces Virtual 2020 Annual Meeting of Stockholders
2020-05-07 12:00 ET
Neuronetics Recognizes Critical Health Professionals During Mental Health Awareness Month
2020-05-05 10:00 ET
Neuronetics Reports First Quarter 2020 Financial and Operating Results
2020-04-21 12:00 ET
Neuronetics to Report First Quarter 2020 Financial and Operating Results and Host Conference Call
2020-04-08 20:11 ET
Neuronetics, Inc. Adopts Limited Duration Shareholder Rights Plan
2020-04-08 20:10 ET
Neuronetics, Inc. Announces Preliminary First Quarter 2020 Revenue, Corporate Restructuring, and Provides Business Update
2020-03-30 11:30 ET
Neuronetics Recognized as 2020 Top Neurology Device Provider
2020-03-16 11:30 ET
Neuronetics® Hits Major Milestones with More Than 2.5 Million Treatments and 1,000 Installations of Its NeuroStar® Advanced Therapy System
2020-03-06 12:30 ET
FDA Grants NeuroStar® Advanced Therapy System Breakthrough Device Designation to Treat Bipolar Depression
2020-03-05 17:54 ET
Neuronetics, Inc. announces Chris Thatcher will step down as President and CEO
2020-03-03 11:00 ET
Neuronetics Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
2020-02-18 13:00 ET
Neuronetics to Report Fourth Quarter and Fiscal Year 2019 Financial and Operating Results and Host Conference Call
2020-01-21 12:30 ET
Neuronetics Appoints Andrew Macan As Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
2019-11-25 12:30 ET
Neuronetics to Present at the 31st Annual Piper Jaffray Healthcare Conference
2019-11-07 12:30 ET
Neuronetics® to Present New Depression Research at 15th Annual Neuroscience Education Institute Congress
2019-11-05 12:30 ET
Neuronetics Reports Third Quarter 2019 Financial and Operating Results
2019-11-01 11:30 ET
Neuronetics® Announces Appointment of Sheryl Conley to its Board of Directors
2019-10-28 11:30 ET
Neuronetics® and Success TMS Partner to Increase Patient Access to Leading Depression Treatment, NeuroStar® Advanced Therapy
2019-10-22 11:30 ET
Neuronetics to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call
2019-10-21 11:30 ET
Neuronetics CEO Chris Thatcher to Ring Nasdaq Closing Bell on October 22 in Honor of National Depression Awareness Month
2019-10-03 11:30 ET
Neuronetics® Unveils Promising New Depression Research Data at Psych Congress
2019-10-01 11:30 ET
Neuronetics® Honors Depression Conquerors For National Depression Awareness Month
2019-09-04 11:30 ET
Neuronetics® Announces Greenbrook® TMS Installation Milestone for NeuroStar® Advanced Therapy System
2019-08-19 11:30 ET
Researchers at USU Unveil Neuronetics®-supported Clinical Research for PTSD and Traumatic Brain Injury at the Military Health System Research Symposium
2019-08-01 11:30 ET
Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy
2019-07-29 11:30 ET
Neuronetics® Launches TrakStar® Plus Patient Data Management System to Maximize Physician Time with Patients
2019-07-08 11:30 ET
NeuroStar® Patient Outcomes Registry Has Now Surpassed 3,000 Evaluable Patients, Making It The World's Largest in Major Depressive Disorder
2019-07-03 01:03 ET
Shareholder Rights Law Firm Johnson Fistel Launches Investigations
2019-05-14 11:30 ET
NeuroStar® Advanced Therapy Survey Finds Majority of Americans Don't Feel Very Equipped to Discuss Depression With Loved Ones

SEC forms

Show financial reports only

SEC form 10
2024-03-08 00:00 ET
Neuronetics published news for 2023 q4
SEC form 8
2024-03-05 07:31 ET
Neuronetics published news for 2023 q4
SEC form 8
2024-03-05 07:31 ET
Neuronetics reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Neuronetics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Neuronetics published news for 2023 q4
SEC form 10
2023-11-07 16:30 ET
Neuronetics published news for 2023 q3
SEC form 8
2023-11-07 07:31 ET
Neuronetics reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Neuronetics published news for 2023 q3
SEC form 10
2023-08-08 16:31 ET
Neuronetics published news for 2023 q2
SEC form 6
2023-08-08 07:31 ET
Neuronetics reported for 2023 q2
SEC form 6
2023-08-08 07:30 ET
Neuronetics published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Neuronetics published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Neuronetics published news for 2023 q2
SEC form 10
2023-05-15 00:00 ET
Neuronetics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Neuronetics published news for 2023 q1
SEC form 6
2023-04-04 09:25 ET
Neuronetics published news for 2023 q1
SEC form 6
2023-03-10 17:28 ET
Neuronetics published news for 2022 q4
SEC form 10
2023-03-07 16:39 ET
Neuronetics reported for 2022 q4
SEC form 6
2023-03-07 07:31 ET
Neuronetics published news for 2022 q4
SEC form 6
2023-03-07 07:30 ET
Neuronetics published news for 2022 q4
SEC form 10
2023-03-07 00:00 ET
Neuronetics reported for 2022 q4
SEC form 8
2023-03-07 00:00 ET
Neuronetics reported for 2022 q4
SEC form 6
2023-02-27 16:16 ET
Neuronetics published news for 2022 q4
SEC form 6
2023-01-09 16:07 ET
Neuronetics published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Neuronetics published news for 2022 q4
SEC form 6
2022-12-29 16:15 ET
Neuronetics published news for 2022 q3
SEC form 10
2022-11-08 16:31 ET
Neuronetics reported for 2022 q3
SEC form 6
2022-11-08 07:32 ET
Neuronetics published news for 2022 q3
SEC form 6
2022-11-08 07:31 ET
Neuronetics published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Neuronetics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Neuronetics reported for 2022 q3
SEC form 6
2022-08-26 16:30 ET
Neuronetics published news for 2022 q2
SEC form 10
2022-08-02 16:31 ET
Neuronetics reported for 2022 q2
SEC form 6
2022-08-02 07:32 ET
Neuronetics published news for 2022 q2
SEC form 6
2022-08-02 07:30 ET
Neuronetics published news for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Neuronetics reported for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Neuronetics reported for 2022 q2
SEC form 6
2022-07-18 16:30 ET
Neuronetics published news for 2022 q2
SEC form 6
2022-05-27 16:30 ET
Neuronetics published news for 2022 q1
SEC form 10
2022-05-12 16:33 ET
Neuronetics reported for 2022 q1
SEC form 6
2022-05-12 07:32 ET
Neuronetics published news for 2022 q1
SEC form 6
2022-05-12 07:30 ET
Neuronetics published news for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Neuronetics reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Neuronetics reported for 2022 q1
SEC form 6
2022-05-05 16:30 ET
Neuronetics published news for 2022 q1
SEC form 6
2022-04-14 16:16 ET
Neuronetics published news for 2022 q1
SEC form 10
2022-03-08 16:31 ET
Neuronetics published news for 2021 q4
SEC form 6
2022-03-08 07:32 ET
Neuronetics published news for 2021 q4
SEC form 6
2022-03-08 07:30 ET
Neuronetics published news for 2021 q4
SEC form 8
2022-03-08 00:00 ET
Neuronetics published news for 2021 q4
SEC form 10
2022-03-08 00:00 ET
Neuronetics published news for 2021 q4
SEC form 6
2022-02-28 16:30 ET
Neuronetics published news for 2021 q4
SEC form 6
2022-02-22 07:30 ET
Neuronetics published news for 2021 q4
SEC form 6
2022-01-10 08:30 ET
Neuronetics published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Neuronetics published news for 2021 q4
SEC form 10
2021-11-09 16:31 ET
Neuronetics published news for 2021 q3
SEC form 6
2021-11-09 07:33 ET
Neuronetics published news for 2021 q3
SEC form 6
2021-11-09 07:30 ET
Neuronetics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Neuronetics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Neuronetics published news for 2021 q3
SEC form 6
2021-10-19 20:17 ET
Neuronetics published news for 2021 q3
SEC form 6
2021-10-12 17:28 ET
Neuronetics published news for 2021 q3
SEC form 8
2021-10-12 00:00 ET
Neuronetics published news for 2021 q3
SEC form 6
2021-10-05 16:29 ET
Neuronetics published news for 2021 q3
SEC form 6
2021-08-05 21:02 ET
Neuronetics published news for 2021 q2
SEC form 10
2021-08-03 16:32 ET
Neuronetics published news for 2021 q2
SEC form 6
2021-08-03 14:55 ET
Neuronetics published news for 2021 q2
SEC form 6
2021-08-03 07:33 ET
Neuronetics published news for 2021 q2
SEC form 6
2021-08-03 07:30 ET
Neuronetics published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Neuronetics published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Neuronetics published news for 2021 q2
SEC form 6
2021-07-02 16:46 ET
Neuronetics published news for 2021 q2
SEC form 6
2021-06-01 19:51 ET
Neuronetics published news for 2021 q1
SEC form 10
2021-05-04 16:32 ET
Neuronetics published news for 2021 q1
SEC form 6
2021-05-04 07:37 ET
Neuronetics published news for 2021 q1
SEC form 6
2021-05-04 07:30 ET
Neuronetics published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Neuronetics published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Neuronetics published news for 2021 q1
SEC form 6
2021-04-14 17:20 ET
Neuronetics published news for 2021 q1
SEC form 6
2021-04-14 16:06 ET
Neuronetics published news for 2021 q1
SEC form 6
2021-04-09 17:00 ET
Neuronetics published news for 2021 q1
SEC form 6
2021-04-05 16:32 ET
Neuronetics published news for 2021 q1
SEC form 6
2021-04-01 16:57 ET
Neuronetics published news for 2021 q1
SEC form 6
2021-03-11 17:15 ET
Neuronetics published news for 2020 q4
SEC form 10
2021-03-02 17:06 ET
Neuronetics published news for 2020 q4
SEC form 6
2021-03-02 07:31 ET
Neuronetics published news for 2020 q4
SEC form 6
2021-03-02 07:30 ET
Neuronetics published news for 2020 q4
SEC form 6
2021-02-02 16:10 ET
Neuronetics published news for 2020 q4
SEC form 6
2021-01-28 16:52 ET
Neuronetics published news for 2020 q4
SEC form 6
2021-01-13 08:01 ET
Neuronetics published news for 2020 q4
SEC form 6
2020-12-08 16:26 ET
Neuronetics published news for 2020 q3
SEC form 10
2020-11-02 17:00 ET
Neuronetics published news for 2020 q3
SEC form 6
2020-11-02 16:11 ET
Neuronetics published news for 2020 q3
SEC form 6
2020-11-02 16:10 ET
Neuronetics published news for 2020 q3